Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Audentes Therapeutics
BOLD

Buy Audentes Therapeutics (BOLD) Stock

BOLD
See BOLD stock price and Buy/Sell Audentes Therapeutics with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
BOLD

Audentes Therapeutics (BOLD)

About Audentes Therapeutics (BOLD)

Audentes Therapeutics doing business as Astellas Gene Therapies, Inc. is a biotechnology company that serves as the Gene Therapy Center of Excellence. The company is divided into three divisions that specialize in gene therapy research, including technical operations, medical and development, and future commercialization of gene therapy programs. Audentes Therapeutics was acquired by Astellas Phar...Read more
Market Cap
$2.76B
1 Year High
$60
Volume
1 Year Low
$22
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

No one owns or watch BOLD stock

Audentes Therapeutics Stock News

Audentes Therapeutics stock rating

What analysts recommend for BOLD stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
3

Audentes Therapeutics price target

What analysts think BOLD will be worth
Low $0
High $60
Current $0
Target $60

Audentes Therapeutics earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.36
-0.71
-1.07
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021

Expected EPS
Q4 2021
-$0.15
Actual EPS
Q4 2021

Buy Audentes Therapeutics (BOLD) Stock

BOLD
See BOLD stock price and Buy/Sell Audentes Therapeutics with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

No one owns or watch BOLD stock
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.